➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Johnson and Johnson
Merck
Boehringer Ingelheim

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUPPRELIN LA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for SUPPRELIN LA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02278185 ↗ Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Recruiting University of Colorado, Denver Phase 2 2015-10-01 This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.
NCT03678025 ↗ Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting National Cancer Institute (NCI) Phase 3 2018-09-17 This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
NCT03678025 ↗ Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting Southwest Oncology Group Phase 3 2018-09-17 This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SUPPRELIN LA

Condition Name

Condition Name for SUPPRELIN LA
Intervention Trials
Recurrent Prostate Cancer 1
Metastatic Prostatic Adenocarcinoma 1
Stage IVB Prostate Cancer AJCC v8 1
Castration Levels of Testosterone 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SUPPRELIN LA
Intervention Trials
Prostatic Neoplasms 2
Adenocarcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SUPPRELIN LA

Trials by Country

Trials by Country for SUPPRELIN LA
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SUPPRELIN LA
Location Trials
Texas 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SUPPRELIN LA

Clinical Trial Phase

Clinical Trial Phase for SUPPRELIN LA
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SUPPRELIN LA
Clinical Trial Phase Trials
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SUPPRELIN LA

Sponsor Name

Sponsor Name for SUPPRELIN LA
Sponsor Trials
National Cancer Institute (NCI) 1
University of Colorado, Denver 1
Southwest Oncology Group 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SUPPRELIN LA
Sponsor Trials
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Johnson and Johnson
Colorcon
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.